Starpharma Holdings Ltd has released a press release.
Starpharma receives $7.1M R&D tax incentive refund
Filed with ASX ·
6ix hasn’t read this filing yet.
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- VIRALEZE Nasal Spray Registered in Indonesia
- Positive AZD0466 clinical data presented by AstraZeneca
- AGM Chairman address and CEO presentation
- VIRALEZE distribution agreement for Hong Kong and Macau
- New clinical data for DEP cabazitaxel in prostate cancer
Later from Starpharma
- Response to ASX Query Letters
- Quarterly Activities Report & Appendix 4C
- Interim Report and Half-Year Financial Results
- HER2-targeted DEP SN38 ADC outperforms in HER2 cancer model
- VIRALEZE Nasal Spray Approved in Malaysia
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma